Jean-François Boileau
Academic title(s):
Associate Professor Surgery and Gerald Bronfman Oncology, McGill University
Location:
Jewish General Hospital
Office:
E-710
Division:
General Surgery
Hospital title:
Director of the Jewish General Hospital Breast Clinical Trials Group
Founding member of the Quebec McPeak-Sirois clinical trials consortium
Degree(s):
MD, MS, FRCSC
Awards, honours, and fellowships:
- 2007 Royal College of Physicians and Surgeons of Canada/ Society of Surgical Oncology/ Canadian Society of Surgical Oncology Fellowship in General Surgical Oncology.
- 2015 Harvey Sigman Teaching Award. Undergraduate Teaching McGill University.
- 2019 Prix Banque Nationale Innovation et Soutien à la Communauté de la Fondation du Cancer du Sein du Québec
Current research:
Senior investigator. “Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer, the TADEN study” (Funded by the Quebec Breast Cancer Foundation)
- PI: Leamarie Meloche-Dumas, Co-Senior Author: Erica Patocskai
- ClinicalTrials.gov Identifier: NCT04671511: https://clinicaltrials.gov/ct2/show/NCT04671511
List of ongoing breast clinical trials at the JGH:
http://mcpeaksirois.org/en/clinical-trials-performed-within-the-group/
Clinical Interests:
Breast Cancer
Language(s) spoken:
English
French
Biography:
Dr. Boileau is associate professor in the Department of Surgery and associate member of the Gerald Bronfman Department of Oncology at McGill University. He is a surgical oncologist and clinician scientist at the Montreal Jewish General Segal Cancer Centre. He is currently the head of the Jewish General Hospital’s Breast Clinical Trial’s Group and a founding member of the Quebec McPeak-Sirois Clinical Trials Consortium.
Dr. Boileau is the Principle Investigator of the SN FNAC study that has helped to establish sentinel node biopsy as an acceptable method to re-stage the axilla of node positive breast cancer patients after neoadjuvant therapy (Published in the Journal of Clinical Oncology).
Selected publications:
- Wong SM, Boileau JF. ASO Author Reflections: Low Rates of Axillary Recurrence in Clinically Node-Positive Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy Alone Following Pathologic Response to Neoadjuvant Chemotherapy. Ann Surg Oncol. 2020 Oct 29. doi: 10.1245/s10434-020-09259-y . Online ahead of print.PMID: 33123855
- Wong SM, Basik M, Florianova L, Margolese R, Dumitra S, Muanza T, Carbonneau A, Ferrario C,Boileau JF. Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg Oncol. 2020 Oct 23. doi: 10.1245/s10434-020-09211-0. Online ahead of print.PMID: 33095362
- Parvez E, Martel K, Morency D, Dumitra S, Meguerditchian AN, Dionisopoulos T, Meterissian S, Basik M, Boileau JF. Surgical and Oncologic Outcomes of Nipple-Sparing Mastectomy for a Cohort of Breast Cancer Patients, Including Cases with High-Risk Features. Clin Breast Cancer. 2020 Aug;20(4):353-358. doi: 10.1016/j.clbc.2020.03.001. Epub 2020 Mar 8.PMID: 32305298
- Safran T, Al-Halabi B, Viezel-Mathieu A, Boileau JF, Dionisopoulos T. DTI, Prepectoral Breast Reconstruction: A Single Surgeon Experience with 201 Consecutive Patients. Plast Reconstr Surg. 2020 Jan 7.
- Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020 Feb 10;38(5):444-453.
- Viezel-Mathieu A, Alnaif N, Aljerian A, Safran T, Brabant G, Boileau JF, Dionisopoulos T. Acellular Dermal Matrix-sparing Direct-to-implant Prepectoral Breast Reconstruction: A Comparative Study Including Cost Analysis. Ann Plast Surg. 2020 Feb;84(2):139-143.
- Morency D, Dumitra S, Parvez E, Martel K, Basik M, Robidoux A, Poirier B, Holloway CMB, Gaboury L, Sideris L, Meterissian S, Boileau JF. Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study. Ann Surg Oncol. 2019 Dec;26(13):4337-4345. doi: 10.1245/s10434-019-07809-7. Epub 2019 Oct 11.
- Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019 Sep 1;37(25):2206-2216. doi: 10.1200/JCO.19.00882. Epub 2019 Jun 3.
- Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, Boileau JF, Provencher L, Robidoux A, Rimawi M, McIntosh SA, Shalaby I, Stein RC, Thirlwell M, Dolling D, Morden J, Snowdon C, Perry S, Cornman C, Batten LM, Jeffs LK, Dodson A, Martins V, Modi A, Osborne CK, Pogue-Geile KL, Cheang MCU, Wolmark N, Julian TB, Fisher K, MacKenzie M, Wilcox M, Huang Bartlett C, Koehler M, Dowsett M, Bliss JM, Jacobs SA. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. J Clin Oncol. 2019 Jan 20;37(3):178-189.
- Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018 Jan;19(1):115-126.
- Wong SM, King T, Boileau JF, Barry WT, Golshan M. Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ. Ann Surg Oncol. 2017 Sep;24(9):2509-2517.
- Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Boileau JF, Brezden-Masley C, Chia S, Dent S, Gelmon K, Paterson A, Rayson D, Berry DA. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncol. 2016 Jun 1;2(6):751-60.
- Simmons CE, Hogeveen S, Leonard R, Rajmohan Y, Han D, Wong A, Lee J, Brackstone M, Boileau JF, Dinniwell R, Gandhi S. A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyond. Curr Oncol. 2015 March; 22(Suppl 1): S43–S53.
- Boileau JF, Poirier B, Basik M, Holloway C, Gaboury L, Sideris L, Meterissian S, Arnaout A, Brackstone M, McCready DR, Karp S, Wright F, Younan R, Provencher L, Patocskai E, Omeroglu A, Robidoux A. Sentinel Node biopsy Following NeoAdjuvant Chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study. J Clin Oncol. 2015 Jan 20;33(3):258-64.
- Verma S, Joy AA, Rayson D, McLeod D, Brezden-Masley C, Boileau JF, Gelmon K. HER Story – The Next Chapter in HER2-Directed Therapy for Advanced Breast Cancer., Oncologist. 2013;18(11):1153-66.
- Boileau JF, Easson A, Escallon JM, Leong WL, Reedijk M, Youngson BJ, McCready DR. Sentinel nodes in breast cancer: relevance of axillary level II nodes and optimal number of nodes that need to be removed. Ann Surg Oncol. 2008 Jun;15(6):1710-6. Principal Author.